TacticScaleWhat Veracyte Does & How It Makes Money (VCYT)
Updated October 2026 · reflects Veracyte's latest reported financials
Genomic diagnostic test company focused on cancer diagnosis. Veracyte earns revenue mainly by selling its genomic classifier tests and assays for cancer diagnosis.
How Veracyte makes money
Veracyte earns revenue mainly by selling its genomic classifier tests and assays for cancer diagnosis. It also earns money from services for its nCounter analysis system.
What Veracyte does
Veracyte, Inc. is a diagnostics company that develops genomic tests for cancer. Its tests help doctors diagnose disease and guide treatment decisions. The lineup includes the Afirma classifier for thyroid nodules, Decipher classifiers for prostate and bladder cancer, the Prosigna breast cancer assay, and the Percepta nasal swab test for lung cancer. The company also provides services for the nCounter analysis system. The company was incorporated in 2006 as Calderome, Inc. and took the Veracyte name in 2008. It is headquartered in South San Francisco, California, and operates in the United States and internationally.
Products & services
- Afirma Genomic Sequencing Classifier
- Decipher Prostate Genomic Classifier
- Decipher Bladder Genomic Classifier
- Prosigna Breast Cancer Assay
- Percepta Nasal Swab Test
- nCounter Analysis System
What is Veracyte worth?
On an owner-earnings DCF, Veracyte's most-likely value is about $86 versus a recent price near $45 (91% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$22) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
NeoGenomics (NEO) · Labcorp (LH) · Revvity (RVTY) · Amoy Diagnostics (300685.SZ) · Quest Diagnostics (DGX)